BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinicalstage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer. "I am very pleased to announce the well-deserved promotions of Sharon, Phil and Jenni ...